Multiple Myeloma × Bendamustine Hydrochloride × Clear all A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Completed
130 enrolled
FT576 in Subjects With Multiple Myeloma
Phase 1 Completed
31 enrolled
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Phase 1 Withdrawn
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Completed
24 enrolled 13 charts
BEB-2
Phase 2 Completed
120 enrolled 11 charts
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Phase 1 Completed
20 enrolled
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Phase 1/2 Terminated
23 enrolled 13 charts
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Phase 1 Completed
18 enrolled 10 charts
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Phase 1/2 Unknown
56 enrolled 12 charts
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase 1/2 Terminated
32 enrolled 18 charts
OPTIMAL
Phase 2 Completed
31 enrolled 13 charts
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma
Phase 3 Unknown
10 enrolled
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Unknown
56 enrolled
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
18 enrolled
BVD
Phase 2 Completed
75 enrolled
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase 1/2 Completed
38 enrolled 18 charts
BPV
Phase 2 Completed
46 enrolled
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
Phase 2 Terminated
11 enrolled 9 charts
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Phase 1/2 Completed
70 enrolled 11 charts
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
Phase 1/2 Completed
57 enrolled 19 charts
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Completed
20 enrolled
BVRD
Phase 1/2 Terminated
3 enrolled 4 charts
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
Phase 2 Completed
30 enrolled
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Phase 2 Terminated
24 enrolled 3 charts
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
Phase 2 Withdrawn
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase 2 Completed
59 enrolled 9 charts
BRd
Phase 2 Completed
50 enrolled
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
Phase 2 Completed
60 enrolled
BBD
Phase 2 Completed
79 enrolled
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/2 Completed
40 enrolled 16 charts
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Unknown
50 enrolled